Literature DB >> 14696972

Prostaglandin E--a powerful anabolic agent for generalized or site-specific bone formation.

Yannis Vrotsos1, Scott C Miller, Sandy C Marks.   

Abstract

Prostaglandins are locally secreted, rapidly metabolized, biologically active fatty acids first identified in the prostate. The role of prostaglandins in the inflammatory response has been widely studied. However, some prostaglandins, particularly those of the E series (PGEs), can suppress inflammation, making it difficult to understand the local events and their sequence. This bimodal potential of the PGEs has been poorly understood in skeletal biology, causing the initial report of PGEs as mediators of bone resorption to persist for more than two decades, despite ample evidence to the contrary. This resulted in part from the power of any initial report to overrule subsequent conflicting views and in part on the exclusive reliance on in vitro data to explain in vivo phenomena. Over a decade ago, the potential of PGEs as authentic anabolic skeletal agents was demonstrated convincingly in vivo by both systemic and local delivery. The potential clinical applications of the PGEs in skeletal biology have not yet been developed. Our purpose is to review the reasons for the delayed discovery of the true skeletal effects of the PGEs and to describe applications for this technology. With the development of appropriate delivery systems, one can anticipate widespread clinical applications of the PGEs to accelerate skeletal repair, and to treat skeletal pathologies and trauma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696972     DOI: 10.1615/critreveukaryotgeneexpr.v13.i24.170

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  5 in total

1.  Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo.

Authors:  J D Bradley; D G Cleverly; A M Burns; N B Helm; M J Schmid; D B Marx; D M Cullen; R A Reinhardt
Journal:  J Periodontal Res       Date:  2007-06       Impact factor: 4.419

2.  Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.

Authors:  Huaizhong Pan; Monika Sima; Scott C Miller; Pavla Kopečková; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2013-06-02       Impact factor: 12.479

3.  Osteotropic beta-cyclodextrin for local bone regeneration.

Authors:  Xin-Ming Liu; Andrew T Wiswall; John E Rutledge; Mohammed P Akhter; Diane M Cullen; Richard A Reinhardt; Dong Wang
Journal:  Biomaterials       Date:  2008-01-15       Impact factor: 12.479

4.  KMN-159, a novel EP4 receptor selective agonist, stimulates osteoblastic differentiation in cultured whole rat bone marrow.

Authors:  Thomas A Owen; Chandni Patel; Shanqiao Wei; Chi S Ho; Kaylah Birmingham; Samuel Sanchez; Natalie Chung; Alexa Cahill; James P O'Malley; Stephen D Barrett; María Inés Morano
Journal:  Gene       Date:  2020-04-22       Impact factor: 3.688

5.  Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.

Authors:  S C Miller; H Pan; D Wang; B M Bowman; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.